ROIV
Roivant Sciences is a biopharmaceutical company developing a diversified pipeline of small molecule inhibitors, monoclonal antibodies, and inhaled activators across immunology and rare disease indications. Lead programs include brepocitinib, a TYK2 and JAK1 inhibitor in Phase 3 development for dermatomyositis and non-infectious uveitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in Phase 2/3 and Phase 3 development respectively across multiple IgG-mediated autoimmune conditions including Graves disease, myasthenia gravis, and thyroid eye disease; and mosliciguat, an inhaled sGC activator in Phase 2 development for pulmonary hypertension associated with interstitial lung disease. Roivant operates through subsidiary
Pipeline
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown.
Catalyst Calendar
“the elimination of fixed quarterly payments totaling $176.3 million that would have been due and payable following regulatory approval of tapinarof in the U.S. for atopic dermatitis, if approved”
“a $75 million milestone payment payable upon FDA approval of VTAMA® (the "Product") for the treatment of atopic dermatitis”
“topline results from Kinevant's Phase 2 RESOLVE-Lung study of namilumab in chronic active pulmonary sarcoidosis”
“topline results from Immunovant's two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease”
“a new Phase 2b/3 clinical program at Priovant for brepocitinib in lichen planopilaris”